On the basis of a meta-analysis of randomized studies assessing reductions in 24 h ambulatory blood pressure, investigators have concluded that hydrochlorothiazide is an inappropriate first-line drug for antihypertensive treatment. This conclusion has the potential to change current prescribing practice for patients with hypertension, but should meta-analyses be considered the ultimate level of evidence, particularly those based on a surrogate outcome?
